{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:38:35Z","timestamp":1789702715850,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>To assess the effectiveness and safety of 0.19-mg fluocinolone acetonide implant (FAc-implant) in inflammatory macular oedema (MO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>This observational, retrospective, multicentre cohort included consecutive eyes treated with FAc-implant between June 2020 and January 2024 for recurrent uveitic or postoperative MO requiring at least two prior dexamethasone-implants (DEX-implants) and \u22656 months of follow-up. The primary endpoints were best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 6, 12, 18, and 24 months. The secondary endpoints were anatomical and functional outcomes, additional treatments and safety outcomes (intraocular pressure (IOP), ocular hypertension (OHT)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 73 eyes were included, with a mean follow-up of 16.8 (8.4) months. The median difference in BCVA was +4.0 [0.0;10.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), +2.0 [0.0;9.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), +5.0 [0.0;10.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010) and +5.0 [0.0;9.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043) letters at 6, 12, 18 and 24 months. The median difference in CMT was -71.0 [-181.3;-25.5] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), -71.0 [-195.0;-30.5] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), -75.0 [194.0;-43.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and -154.0 [-253.0;-110.0] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) \u03bcm at 6, 12, 18 and 24 months. Over the follow-up, 38 eyes (52.1%) did not require any additional intravitreal treatment. At 12 months after FAc-implant, the probability of not receiving a rescue injection of DEX-implant was 54.0% [43.0%;67.0%]. Eight eyes (11.0%) developed OHT (IOP\u2009\u2265\u200925\u2009mmHg or an increase in IOP\u2009\u2265\u200910\u2009mmHg), mostly resolved by IOP-lowering eye drops; two eyes required surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-life study shows the functional and anatomical effectiveness of the FAcimplant in recurrent inflammatory MO, with limited adverse effects and a reduced treatment burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04381-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:51:06Z","timestamp":1773939066000},"page":"1145-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of intravitreal fluocinolone acetonide implant in inflammatory macular oedema"],"prefix":"10.1038","volume":"40","author":[{"given":"Chlo\u00e9","family":"Gullon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3663-8182","authenticated-orcid":false,"given":"Sandra","family":"Elbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Romain-Scelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Burillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3978","authenticated-orcid":false,"given":"Corinne","family":"Dot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1872","authenticated-orcid":false,"given":"Thibaud","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-4064","authenticated-orcid":false,"given":"Yasmine","family":"Serrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Devin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-6716","authenticated-orcid":false,"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"4381_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MS, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4381_CR2","first-page":"557","volume":"96","author":"AJ Flach","year":"1998","unstructured":"Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557\u2013634.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"4381_CR3","first-page":"850","volume":"70","author":"L Claudio","year":"1994","unstructured":"Claudio L, Martiney LA, Brosnan CF. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1\u03b2 or tumor necrosis factor-\u03b1. Lab Invest. 1994;70:850\u201361.","journal-title":"Lab Invest"},{"key":"4381_CR4","first-page":"2418","volume":"19","author":"L Chu","year":"2013","unstructured":"Chu L, Wang B, Xu B, Dong N. Aqueous cytokines as predictors of macular edema in nondiabetic patients following uncomplicated phacoemulsification cataract surgery. Mol Vis. 2013;19:2418\u201325.","journal-title":"Mol Vis"},{"key":"4381_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/archopht.1985.01050010032011","volume":"103","author":"LM Jampol","year":"1985","unstructured":"Jampol LM, Kraff MC, Sanders DR, Alexander K, Lieberman H. Near-UV radiation from the operating microscope and pseudophakic cystoid macular edema. Arch Ophthalmol. 1985;103:28\u201330.","journal-title":"Arch Ophthalmol"},{"key":"4381_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1874364101105010035","volume":"5","author":"MR Martinez","year":"2011","unstructured":"Martinez MR, Ophir A. Pseudophakic cystoid macular edema associated with extrafoveal vitreoretinal traction. Open Ophthalmol J. 2011;5:35\u201341.","journal-title":"Open Ophthalmol J"},{"key":"4381_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","volume":"127","author":"GJ Jaffe","year":"2020","unstructured":"Jaffe GJ, Pavesio CE. Study Investigators. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127:1395\u2013404.","journal-title":"Ophthalmology"},{"key":"4381_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100403","volume":"4","author":"J Biswas","year":"2024","unstructured":"Biswas J, Tyagi M, Agarwal M, Mahendradas P, Shukla D, Sharma K, et al. The 0.2-\u03bcg\/day fluocinolone acetonide intravitreal implant in chronic noninfectious posterior uveitis: a 3-year randomized trial in India. Ophthalmol Sci. 2024;4:100403.","journal-title":"Ophthalmol Sci"},{"key":"4381_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-020-00225-z","volume":"10","author":"B Bodaghi","year":"2020","unstructured":"Bodaghi B, Nguyen QD, Jaffe G, Khoramnia R, Pavesio C. Preventing relapse in noninfectious uveitis affecting the posterior segment of the eye \u2013 evaluating the 0.2\u2009\u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN). J Ophthalmic Inflamm Infect. 2020;10:32.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"4381_CR10","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/11206721221080288","volume":"32","author":"L Kodjikian","year":"2022","unstructured":"Kodjikian L, Bandello F, de Smet M, Dot C, Zarranz-Ventura J, Loewenstein A, et al. Fluocinolone acetonide implant in diabetic macular edema: international experts\u2019 panel consensus guidelines and treatment algorithm. Eur J Ophthalmol. 2022;32:1890\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"4381_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/pharmaceutics16091183","volume":"16","author":"L Sejournet","year":"2024","unstructured":"Sejournet L, Mathis T, Vermot-Desroches V, Serra R, Fenniri I, Denis P, et al. Efficacy and safety of fluocinolone acetonide implant in diabetic macular edema: practical guidelines from reference center. Pharmaceutics. 2024;16:1183.","journal-title":"Pharmaceutics"},{"key":"4381_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41433-021-01608-9","volume":"36","author":"C Pavesio","year":"2022","unstructured":"Pavesio C, Heinz C. Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. Eye. 2022;36:1231\u20137.","journal-title":"Eye"},{"key":"4381_CR13","doi-asserted-by":"crossref","unstructured":"Buhl L, Thurau S, Kern C. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study. Graefes Arch Clin Exp Ophthalmol. 2023;261:1101\u20138.","DOI":"10.1007\/s00417-022-05893-2"},{"key":"4381_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40123-021-00426-2","volume":"11","author":"M Battista","year":"2022","unstructured":"Battista M, Starace V, Cicinelli MV, Capone L, Marchese A, Modorati G, et al. Efficacy of 0.19 mg fluocinolone acetonide implant in non-infectious posterior uveitis evaluated as area under the curve. Ophthalmol Ther. 2022;11:215\u201324.","journal-title":"Ophthalmol Ther"},{"key":"4381_CR15","doi-asserted-by":"crossref","unstructured":"Motloch K, Soler V, Delyfer MN, Vasseur V, Wolff B, Issa M, et al. Efficacy and safety of 0.19-mg fluocinolone acetonide implant in postoperative cystoid macular edema after pars plana vitrectomy: the ILUCYD study. Ophthalmol Retina. 2024;8:1181\u201391.","DOI":"10.1016\/j.oret.2024.07.004"},{"key":"4381_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-024-00427-9","volume":"14","author":"RA Sisk","year":"2024","unstructured":"Sisk RA, Kiernan DF, Almeida D, Kolomeyer AM, Eichenbaum D, Kitchens JW. Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to noninfectious uveitis: a case series of 15 patients. J Ophthalmic Inflamm Infect. 2024;14:44.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"4381_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/IAE.0000000000003765","volume":"43","author":"JD Deaner","year":"2023","unstructured":"Deaner JD, Mammo D, Gross A, Lee T, Sharma S, Srivastava SK, et al. 0.18 mg fluocinolone acetonide insert for the treatment of chronic postoperative pseudophakic cystoid macular edema. Retina. 2023;43:897\u2013904.","journal-title":"Retina"},{"key":"4381_CR18","doi-asserted-by":"crossref","unstructured":"Chronopoulos A, Chronopoulos P, Hattenbach LO, Ashurov A, Schutz JS, Pfeiffer N, et al. Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema \u2013 two years results. Eur J Ophthalmol. 2023;33:1054\u201360.","DOI":"10.1177\/11206721221124688"},{"key":"4381_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40123-022-00613-9","volume":"12","author":"M Lima-Fontes","year":"2023","unstructured":"Lima-Fontes M, Leuzinger-Dias M, Barros-Pereira R, Fernandes V, Falc\u00e3o M, Falc\u00e3o-Reis F, et al. Intravitreal fluocinolone acetonide implant (FAc, 0.19 mg, ILUVIEN) in the treatment of patients with recurrent cystoid macular edema after pars plana vitrectomy. Ophthalmol Ther. 2023;12:377\u201388.","journal-title":"Ophthalmol Ther"},{"key":"4381_CR20","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1097\/IAE.0000000000003855","volume":"43","author":"KG Patel","year":"2023","unstructured":"Patel KG, Flores J, Abbey AM. Injectable fluocinolone implant for the management of chronic postsurgical cystoid macular edema in vitrectomized eyes. Retina. 2023;43:1732\u20137.","journal-title":"Retina"},{"key":"4381_CR21","first-page":"333","volume":"101","author":"D Bellocq","year":"2017","unstructured":"Bellocq D, Pierre-Kahn V, Matonti F, Burillon C, Voirin N, Dot C, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. Br J Ophthalmol. 2017;101:333\u201341.","journal-title":"Br J Ophthalmol"},{"key":"4381_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/mi.2023.99","volume":"3","author":"S Koksaldi","year":"2023","unstructured":"Koksaldi S, Kayaba\u015fi M, Ayhan Z, Kaya M, \u00d6zt\u00fcrk T, Yaman A, et al. Dexamethasone intravitreal implant for macular edema and some other rare indications in uveitis. Med Int. 2023;3:39.","journal-title":"Med Int"},{"key":"4381_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/IAE.0000000000002901","volume":"41","author":"T Mathis","year":"2021","unstructured":"Mathis T, Cerquaglia A, Weber M, Guillarme-Sallit R, Malcl\u00e8s A, Voirin N, et al. Uveitis treated with dexamethasone implant. Retina. 2021;41:620\u20139.","journal-title":"Retina"},{"key":"4381_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/jpm14030245","volume":"14","author":"M Jabbour","year":"2024","unstructured":"Jabbour M, Kodjikian L, Bourdin A, Rougier MB, Serrar Y, Weber M, et al. Efficacy and safety of the fluocinolone acetonide implant in uveitic macular edema: a real-life study from the French Uveitis Network. J Pers Med. 2024;14:245.","journal-title":"J Pers Med"},{"key":"4381_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics14040723","volume":"14","author":"T Mathis","year":"2022","unstructured":"Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, et al. Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc study. Pharmaceutics. 2022;14:723.","journal-title":"Pharmaceutics"},{"key":"4381_CR26","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.jfo.2023.05.001","volume":"46","author":"C Dot","year":"2023","unstructured":"Dot C, Poli M, Aptel F, Denis P, Baudouin C, Nordmann JP, et al. Ocular hypertension and intravitreal steroids injections, update in 2023. French guidelines of the French glaucoma society and the French ophthalmology society. J Fr Ophtalmol. 2023;46:e249\u2013e56.","journal-title":"J Fr Ophtalmol"},{"key":"4381_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, Bailey C, Varma D, Larsen M, et al. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103:1072\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4381_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","volume":"36","author":"C Bailey","year":"2022","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Dowson L, et al. Extended realworld experience with the ILUVIEN (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye. 2022;36:1012\u20138.","journal-title":"Eye"},{"key":"4381_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","volume":"8","author":"A Eaton","year":"2019","unstructured":"Eaton A, Koh SS, Jimenez J, Riemann CD. The USER Study: a chart review of patients receiving a 0.2 \u00b5g\/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8:51\u201362.","journal-title":"Ophthalmol Ther"},{"key":"4381_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ophtha.2014.09.008","volume":"122","author":"DB Moore","year":"2015","unstructured":"Moore DB, Jaffe GJ, Asrani S. Retinal nerve fiber layer thickness measurements: uveitis, a major confounding factor. Ophthalmology. 2015;122:511\u20137.","journal-title":"Ophthalmology"},{"key":"4381_CR31","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1007\/s10792-023-02828-6","volume":"43","author":"A Moll-Udina","year":"2023","unstructured":"Moll-Udina A, Hernanz I, Sainz-de-la-Maza M, Pelegr\u00edn L, Coelho-Borges AI, Pazos M, et al. Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN\u00ae) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. Int Ophthalmol. 2023;43:4181\u201395.","journal-title":"Int Ophthalmol"},{"key":"4381_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.oret.2022.07.002","volume":"7","author":"AK Reddy","year":"2023","unstructured":"Reddy AK, Pecen PE, Patnaik JL, Palestine AG. Single institution experience of intravitreal 0.18-mg fluocinolone acetonide implant for noninfectious uveitis. Ophthalmol Retin. 2023;7:67\u201371.","journal-title":"Ophthalmol Retin"},{"key":"4381_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00417-021-05504-6","volume":"260","author":"A Studsgaard","year":"2022","unstructured":"Studsgaard A, Clemmensen K\u00d8, Nielsen MS. Intravitreal fluocinolone acetonide 0.19 mg (Iluvien) for the treatment of uveitic macular oedema: two-year follow-up of 20 patients. Graefes Arch Clin Exp Ophthalmol. 2022;260:1633\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4381_CR34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00417-020-04614-x","volume":"258","author":"CX Cai","year":"2020","unstructured":"Cai CX, Skalak C, Keenan RT, Grewal DS, Jaffe GJ. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Graefes Arch Clin Exp Ophthalmol. 2020;258:1023\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04381-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:59:30Z","timestamp":1779368370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04381-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4381"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04381-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest to disclose. None of the authors are advisors to Alimera Sciences\/Horus Pharma or related companies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}